The Efficacy of 3 Years Alendronate Therapy in Postmenopausal Chinese Women with Osteoporosis

陈瑾瑜,盛正妍,游利,陈琳,潘凌

DOI: https://doi.org/10.3969/j.issn.1006-7108.2009.04.012

2009-01-01

Abstract:Objective To study the efficacy of 3 years alendronate therapy in postmenopausal Chinese women with osteoporosis,and to explore the relationship between early changes in biochemical markers of bone turnover and 3 years response in bone mineral density (BMD).Methods From Aug 2005 to Jan 2006,115 postmenopausal Chinese women with established osteoporosis were enrolled from the outpatient department of osteoporosis,Shanghai First People's Hospital. 70 mg per week alendronate and 800 mg calcium plus 0.25 μg calcitriol supplement were used for up to 3 years. Biochemical markers of bone turnover and BMD in lumbar spine,femoral neck,and total hip were measured. Statistical analysis was carried out using the SPSS 13.0 for Windows.Results 3 years alendronate therapy produced a significant increase in BMD at the lumbar spine (8.1%),femoral neck (3.5%),and total hip (4.0%) (all P0.01). At 6 months,serum alkaline phosphatase (ALP),serum osteocalcin(OC),and urine calcium/creatinine (uCa/Cr) were significantly decreased from baseline (16.7%,24.1%,and 13.4%,respectively,all P0.01). After then,those biochemical markers of bone turnover remained in a low level. Pearson studies revealed that 6 months changes in OC and uCa/Cr were negative correlated with 3 years changes in BMD at the lumbar spine,femoral neck,and total hip (all P0.01). 6 months changes in ALP was also associated with 3 years changes in lumbar spine BMD (r=-0.231 ,P0.01).4 cases of new fracture occurred during treatment.Conclusion Alendronate was effective and safe in post menopausal Chinese women with osteoporosis. 3 years alendronate therapy produced efficacies in increasing in BMD and decreasing in markers of bone turnover,and the early changes in markers of bone turnover were associated with long-term improvement in BMD.